TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel Group, 52-Week Study to Compare the Effect of Fluticasone Propionate/Salmeterol Diskus Combination Product 250/50mcg BID With Salmeterol Diskus 50mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease
Brief Summary: This study evaluates the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease) exacerbations. This study will last up to 56 weeks, and subjects will visit the clinic 10 times. Subjects will be given breathing tests and will record their breathing symptoms daily on diary cards. All study related medicines and medical examinations will be provided at no cost. The two drugs used in this study have been approved by FDA for use in patients with COPD.


Options:
A: Intervention Type: DRUG; Name: Fluticasone Propionate/Salmeterol Combination Product; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): N/A
B: Arm Label: Fluticasone Furoate Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF Inhalation Powder | Arm Label: FF Inhalation Pwdr; Type: EXPERIMENTAL; Interventions: Drug: FF Inhalation Powder | Arm Label: Fluticasone Furoate/GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Pwdr; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FF Inhalation Powder; Assigned to Arm(s): FF Inhalation Pwdr, Fluticasone Furoate Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Pwdr, Fluticasone Furoate/GW642444 Inhalation Powder | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 Inhalation Powder | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Budesonide/formoterol pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Budesonide pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Formoterol Turbuhaler; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV Transmission
Brief Summary: The purpose of this study is to determine if extended antiretroviral regimens given to the infant during the first 14 weeks of age would decrease breast milk transmission of HIV.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine, Drug: AZT, Drug: NVP and AZT | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine, Drug: AZT, Drug: NVP+AZT | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine, Drug: NVP | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: AZT; Assigned to Arm(s): A, C | Intervention Type: DRUG; Name: NVP and AZT; Assigned to Arm(s): A | Intervention Type: DRUG; Name: NVP; Assigned to Arm(s): B | Intervention Type: DRUG; Name: NVP+AZT; Assigned to Arm(s): C
B: Intervention Type: DRUG; Name: Zidovudine/Lamivudine and either Nevirapine or Nelfinavir; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding for 6 months postpartum; Assigned to Arm(s): N/A
C: Arm Label: Maternal ARVs & Nutrition Supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: Maternal zidovudine/lamivudine/lopinavir-ritonavir, Dietary Supplement: Maternal protein and calorie supplement | Arm Label: Infant NVP & Nutrition Supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infant nevirapine, Dietary Supplement: Maternal protein and calorie supplement | Arm Label: Maternal ARVs & No Nutrition Supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: Maternal zidovudine/lamivudine/lopinavir-ritonavir | Arm Label: Infant NVP & No Nutrition Supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infant nevirapine | Arm Label: No Drugs & Nutrition Supplement; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Maternal protein and calorie supplement | Arm Label: No Drugs & No Nutrition Supplement; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Maternal zidovudine/lamivudine/lopinavir-ritonavir; Assigned to Arm(s): Maternal ARVs & No Nutrition Supplement, Maternal ARVs & Nutrition Supplement | Intervention Type: DRUG; Name: Infant nevirapine; Assigned to Arm(s): Infant NVP & No Nutrition Supplement, Infant NVP & Nutrition Supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Maternal protein and calorie supplement; Assigned to Arm(s): Infant NVP & Nutrition Supplement, Maternal ARVs & Nutrition Supplement, No Drugs & Nutrition Supplement
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine, Drug: HIV immune globulin solution | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: HIV immune globulin solution; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV Transmission
Brief Summary: The purpose of this study is to determine if extended antiretroviral regimens given to the infant during the first 14 weeks of age would decrease breast milk transmission of HIV.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine, Drug: AZT, Drug: NVP and AZT | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine, Drug: AZT, Drug: NVP+AZT | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine, Drug: NVP | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: AZT; Assigned to Arm(s): A, C | Intervention Type: DRUG; Name: NVP and AZT; Assigned to Arm(s): A | Intervention Type: DRUG; Name: NVP; Assigned to Arm(s): B | Intervention Type: DRUG; Name: NVP+AZT; Assigned to Arm(s): C
B: Arm Label: Abrupt Weaning; Type: EXPERIMENTAL; Interventions: Other: abrupt weaning at 4 months | Arm Label: Exclusive breastfeeding per WHO guidelines; Type: ACTIVE_COMPARATOR; Interventions: Other: Continued exclusive breastfeeding | Intervention Type: OTHER; Name: abrupt weaning at 4 months; Assigned to Arm(s): Abrupt Weaning | Intervention Type: OTHER; Name: Continued exclusive breastfeeding; Assigned to Arm(s): Exclusive breastfeeding per WHO guidelines
C: Arm Label: maternal nevirapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine | Arm Label: maternal placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: No intervention | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): maternal nevirapine | Intervention Type: DRUG; Name: No intervention; Assigned to Arm(s): maternal placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine, Drug: HIV immune globulin solution | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: HIV immune globulin solution; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nicotine Replacement Treatment for Pregnant Smokers
Brief Summary: Smoking during pregnancy is an important modifiable cause of poor pregnancy outcomes. Even with augmented behavioral interventions, smoking cessation rates in pregnancy trials rarely exceed 20%. These low quit rates may be due to inadequate treatment of the physical dependence on nicotine. Indeed, medications, which may help to reduce nicotine withdrawal symptoms, are a first-line treatment for smoking treatment in non-pregnant smokers. However, little information is available on the safety or efficacy of medications to treat pregnant smokers.

The purpose of this trial is to evaluate the safety and effectiveness of 2 mg nicotine gum in promoting smoking cessation during pregnancy. The design is a randomized, placebo controlled trial where subjects are randomized to nicotine gum (6 weeks ad libitum use followed by a 6 week taper) or a matching placebo. Women who are doing well at the end of the trial will also be offered gum post-partum for relapse prevention.


Options:
A: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: 2 mg nicotine polacrilex | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: 2 mg nicotine polacrilex; Assigned to Arm(s): B
B: Intervention Type: BEHAVIORAL; Name: Nicotine Replacement Therapy; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nicotine Replacement Treatment for Pregnant Smokers
Brief Summary: Smoking during pregnancy is an important modifiable cause of poor pregnancy outcomes. Even with augmented behavioral interventions, smoking cessation rates in pregnancy trials rarely exceed 20%. These low quit rates may be due to inadequate treatment of the physical dependence on nicotine. Indeed, medications, which may help to reduce nicotine withdrawal symptoms, are a first-line treatment for smoking treatment in non-pregnant smokers. However, little information is available on the safety or efficacy of medications to treat pregnant smokers.

The purpose of this trial is to evaluate the safety and effectiveness of 2 mg nicotine gum in promoting smoking cessation during pregnancy. The design is a randomized, placebo controlled trial where subjects are randomized to nicotine gum (6 weeks ad libitum use followed by a 6 week taper) or a matching placebo. Women who are doing well at the end of the trial will also be offered gum post-partum for relapse prevention.


Options:
A: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: 2 mg nicotine polacrilex | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: 2 mg nicotine polacrilex; Assigned to Arm(s): B
B: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine versus placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: nicotine versus placebo | Intervention Type: DRUG; Name: nicotine versus placebo; Assigned to Arm(s): A, B
C: Arm Label: Nicotrol Inhaler; Type: EXPERIMENTAL; Interventions: Drug: Nicotrol Inhaler | Arm Label: Placebo Inhaler; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Inhaler | Intervention Type: DRUG; Name: Nicotrol Inhaler; Assigned to Arm(s): Nicotrol Inhaler | Intervention Type: DRUG; Name: Placebo Inhaler; Assigned to Arm(s): Placebo Inhaler
D: Intervention Type: BEHAVIORAL; Name: Nicotine Replacement Therapy; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nicotine Replacement Treatment for Pregnant Smokers
Brief Summary: Smoking during pregnancy is an important modifiable cause of poor pregnancy outcomes. Even with augmented behavioral interventions, smoking cessation rates in pregnancy trials rarely exceed 20%. These low quit rates may be due to inadequate treatment of the physical dependence on nicotine. Indeed, medications, which may help to reduce nicotine withdrawal symptoms, are a first-line treatment for smoking treatment in non-pregnant smokers. However, little information is available on the safety or efficacy of medications to treat pregnant smokers.

The purpose of this trial is to evaluate the safety and effectiveness of 2 mg nicotine gum in promoting smoking cessation during pregnancy. The design is a randomized, placebo controlled trial where subjects are randomized to nicotine gum (6 weeks ad libitum use followed by a 6 week taper) or a matching placebo. Women who are doing well at the end of the trial will also be offered gum post-partum for relapse prevention.


Options:
A: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: 2 mg nicotine polacrilex | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: 2 mg nicotine polacrilex; Assigned to Arm(s): B
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate | Arm Label: bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion hydrochloride | Arm Label: Nicotine Replacement Therapy Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline tartrate; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: bupropion hydrochloride; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: Nicotine Replacement Therapy Patch; Assigned to Arm(s): Nicotine Replacement Therapy Patch
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: nicotine patch | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: nicotine lozenge | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: nicotine patch + nicotine lozenge | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bupropion | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: bupropion + lozenge | Arm Label: 6; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine lozenge; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: nicotine patch + nicotine lozenge; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: bupropion + lozenge; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 6
D: Intervention Type: DRUG; Name: rimonabant (SR141716); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nicotine Replacement Treatment for Pregnant Smokers
Brief Summary: Smoking during pregnancy is an important modifiable cause of poor pregnancy outcomes. Even with augmented behavioral interventions, smoking cessation rates in pregnancy trials rarely exceed 20%. These low quit rates may be due to inadequate treatment of the physical dependence on nicotine. Indeed, medications, which may help to reduce nicotine withdrawal symptoms, are a first-line treatment for smoking treatment in non-pregnant smokers. However, little information is available on the safety or efficacy of medications to treat pregnant smokers.

The purpose of this trial is to evaluate the safety and effectiveness of 2 mg nicotine gum in promoting smoking cessation during pregnancy. The design is a randomized, placebo controlled trial where subjects are randomized to nicotine gum (6 weeks ad libitum use followed by a 6 week taper) or a matching placebo. Women who are doing well at the end of the trial will also be offered gum post-partum for relapse prevention.


Options:
A: Arm Label: Standard support; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reactive (standard) telephone support | Arm Label: Proactive telephone support; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Proactive telephone support | Arm Label: Standard support & offer NRT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reactive (standard) telephone support, Drug: Offer of voucher for cost-free Nicotine Replacement Therapy | Arm Label: Proactive support & offer NRT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Proactive telephone support, Drug: Offer of voucher for cost-free Nicotine Replacement Therapy | Intervention Type: BEHAVIORAL; Name: Proactive telephone support; Assigned to Arm(s): Proactive support & offer NRT, Proactive telephone support | Intervention Type: BEHAVIORAL; Name: Reactive (standard) telephone support; Assigned to Arm(s): Standard support, Standard support & offer NRT | Intervention Type: DRUG; Name: Offer of voucher for cost-free Nicotine Replacement Therapy; Assigned to Arm(s): Proactive support & offer NRT, Standard support & offer NRT
B: Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): N/A
C: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: 2 mg nicotine polacrilex | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: 2 mg nicotine polacrilex; Assigned to Arm(s): B
D: Intervention Type: BEHAVIORAL; Name: Nicotine Replacement Therapy; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nicotine Replacement Treatment for Pregnant Smokers
Brief Summary: Smoking during pregnancy is an important modifiable cause of poor pregnancy outcomes. Even with augmented behavioral interventions, smoking cessation rates in pregnancy trials rarely exceed 20%. These low quit rates may be due to inadequate treatment of the physical dependence on nicotine. Indeed, medications, which may help to reduce nicotine withdrawal symptoms, are a first-line treatment for smoking treatment in non-pregnant smokers. However, little information is available on the safety or efficacy of medications to treat pregnant smokers.

The purpose of this trial is to evaluate the safety and effectiveness of 2 mg nicotine gum in promoting smoking cessation during pregnancy. The design is a randomized, placebo controlled trial where subjects are randomized to nicotine gum (6 weeks ad libitum use followed by a 6 week taper) or a matching placebo. Women who are doing well at the end of the trial will also be offered gum post-partum for relapse prevention.


Options:
A: Intervention Type: BEHAVIORAL; Name: Nicotine Replacement Therapy; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): N/A
C: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: 2 mg nicotine polacrilex | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: 2 mg nicotine polacrilex; Assigned to Arm(s): B
D: Arm Label: a self help smoking cessation guide; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Guia -a self help smoking cessation guide | Arm Label: couple-based counseling for smoking cessation plus Guia; Type: EXPERIMENTAL; Interventions: Behavioral: couple-based counseling for smoking cessation plus self-help smoking cessation guide | Intervention Type: BEHAVIORAL; Name: couple-based counseling for smoking cessation plus self-help smoking cessation guide; Assigned to Arm(s): couple-based counseling for smoking cessation plus Guia | Intervention Type: BEHAVIORAL; Name: Guia -a self help smoking cessation guide; Assigned to Arm(s): a self help smoking cessation guide

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Aerobic Versus Resistance Exercise Training in Enhancing Quality of Life in Early Stage Breast Cancer Survivors Receiving Chemotherapy: A Multi-Centre Randomized Trial
Brief Summary: The purpose of this study is to compare the effects of two different types of exercise, aerobic exercise training (AET) and resistance exercise training (RET), on quality of life (QoL) in early stage breast cancer survivors receiving chemotherapy. It is hypothesized that both AET and RET would have beneficial effects on QoL.


Options:
A: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic exercise intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Aerobic exercise intervention; Assigned to Arm(s): Exercise
B: Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Resistance Exercise Training; Assigned to Arm(s): N/A
C: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise Training | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Training; Assigned to Arm(s): Exercise
D: Arm Label: Web-based, Stage-matched Exercise and Diet Planning program; Type: EXPERIMENTAL; Interventions: Behavioral: Web-based Health Planner on diet and exercise | Arm Label: Non-tailored booklet on exercise and diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Non-tailored booklet on exercise and diet | Intervention Type: BEHAVIORAL; Name: Web-based Health Planner on diet and exercise; Assigned to Arm(s): Web-based, Stage-matched Exercise and Diet Planning program | Intervention Type: BEHAVIORAL; Name: Non-tailored booklet on exercise and diet; Assigned to Arm(s): Non-tailored booklet on exercise and diet

Answer: B